Press Enter to search · ESC to close

Macro

China NMPA Approves Innovative Antibiotic Iminexifor for Hospital-Acquired Pneumonia

China’s National Medical Products Administration approved the marketing of iminexifor for injection (brand name Funokai), a Class 1 innovative drug developed by Suzhou Sinovent Pharmaceuticals, for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). The drug is indicated for patients aged 18 and older with infections caused by susceptible Gram-negative bacteria including Klebsiella pneumoniae, Acinetobacter baumannii complex, Pseudomonas aeruginosa, Haemophilus influenzae, Klebsiella aerogenes, Enterobacter cloacae, Escherichia coli and Klebsiella oxytoca.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback